| Trial Identifier: | ACE-CL-110 |
| Sponsor: | AcertaPharma |
| NCTID:: | NCT03328273 |
| Start Date: | July 2020 |
| Primary Completion Date: | September 2021 |
| Study Completion Date: | June 2023 |
| Condition: | CLL (Chronic Lymphocytic Leukemia) |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| Polish Translation |
| Country | Location |
|---|---|
| GB | Birmingham, GB, B9 5SS |
| GB | Bournemouth, GB, BH7 7DW |
| GB | Cambridge, GB, CB2 0QQ |
| GB | Cardiff, GB, CF14 4XW |
| GB | Leeds, GB, LS9 7TF |
| GB | Liverpool, GB, L7 8XP |
| GB | London, GB, SE5 9RS |
| GB | London, GB, EC1A 7BE |
| GB | London, GB, NW1 2PG |
| GB | Maidstone, GB, ME16 9QQ |
| GB | Manchester, GB, M20 4BX |
| GB | Nottingham, GB, NG5 1PB |
| GB | Oxford, GB, OX3 7LJ |
| GB | Southampton, GB, SO16 6YD |
| PL | Kraków, PL, 30-510 |
| PL | Łódź, PL, 93-510 |
| PL | Lublin, PL, 20-090 |
| PL | Warszawa, PL, 02-776 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company